Here's Why IBM Is a Buy After a 25% Crash (and Why It Isn't)

IBM attributed a significant part of its Q2 weakness to delayed deals rather than lost demand, but Q3 will test that explanation. Software growth, Consulting revenue, Red Hat and free cash flow are identified as key indicators of whether the sell-off was temporary or reflects a more difficult business shift.

Analysis

IBM: Q3 is a conversion test, not just a rebound test. If delayed projects close, revenue recovery should be accompanied by evidence in bookings/backlog and cash collection; revenue alone could flatter the quarter without resolving execution or cash-conversion concerns. If customers are instead shrinking or reprioritizing projects, longer sales cycles would expose IBM Consulting to competition from Accenture and cloud-native alternatives, while weaker Red Hat and software trends would undermine the higher-quality-growth case. These are conditional competitive risks, not evidence of share loss.

Near term, volatility is likely to track Q3 guidance and deal conversion. Over 1–3 months, watch software and Red Hat growth, Consulting bookings, and free-cash-flow conversion together: strength in only one metric would be a weaker confirmation. Over 6–18 months, sustained software momentum could support a more durable mix improvement; repeated slippage or weak cash conversion would suggest the issue is structural rather than timing-related. The article supplies no valuation or consensus data, so the size of any prior overreaction cannot be established. The contrarian opportunity is to avoid treating management’s timing explanation as proven before cash and bookings corroborate it.

Key Decisions for Investors

• Do not chase a bounce solely on management’s delayed-deal explanation. Treat Q3 as the confirmation point; verify deal conversion against bookings/backlog and free cash flow before adding exposure.
• For an event-driven approach, consider a small, defined-risk IBM position only if Q3 shows improving software/Red Hat trends, Consulting conversion, and cash generation together. Otherwise remain neutral rather than assuming the sell-off is overdone.
• Falsify the recovery thesis if Q3 guidance weakens, delayed deals fail to convert, or free-cash-flow conversion deteriorates despite reported revenue improvement. Reassess positively if conversion and cash metrics strengthen together.
• Monitor Accenture and cloud-platform competitors as possible alternatives if IBM project delays persist, but do not infer competitor share gains without customer or bookings evidence.